Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2003 2
2004 3
2005 6
2006 5
2007 6
2008 11
2009 4
2010 13
2011 9
2012 12
2013 6
2014 6
2015 10
2016 13
2017 12
2018 23
2019 27
2020 30
2021 27
2022 36
2023 24
2024 43
2025 57
2026 45

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

377 results

Results by year

Filters applied: . Clear all
Page 1
A multicentre randomized double-blind placebo-controlled phase III study of the efficacy and safety of xeligekimab (GR1501) in patients with moderate-to-severe plaque psoriasis.
Cai L, Jiang C, Zhang G, Fang H, Wang J, Li Y, Xu H, Xiao R, Ding Y, Huang K, Zhang C, Zhang L, Chen B, Duan X, Pan W, Han G, Chen R, Liu L, Zhang S, Tao J, Pang X, Yu J, Wang H, Zhao Y, Li C, Kang X, Qin L, Zhu X, Su J, Li S, Yang C, Feng W, Lei T, Jiang S, Fang R, Lin M, Lu Q, Xu C, Wang W, Zhang J. Cai L, et al. Among authors: wang j. Br J Dermatol. 2024 Aug 14;191(3):336-343. doi: 10.1093/bjd/ljae062. Br J Dermatol. 2024. PMID: 38366639 Clinical Trial.
LncRNAs in ovarian cancer.
Wang JY, Lu AQ, Chen LJ. Wang JY, et al. Clin Chim Acta. 2019 Mar;490:17-27. doi: 10.1016/j.cca.2018.12.013. Epub 2018 Dec 13. Clin Chim Acta. 2019. PMID: 30553863 Review.
Patient-Reported Outcomes in Adults with Moderate-to-Severe Atopic Dermatitis Treated with Stapokibart over 52 weeks: A Post Hoc Analysis of a Phase 3 Trial.
Zhao Y, Zhang L, Wu L, Yang B, Wang J, Li Y, Diao Q, Li J, Sun Q, Zhu X, Man X, Wang L, Feng Y, Cai T, Zeng H, Li L, Lu J, Ren H, Li F, Lu Q, Tao X, Xiao R, Ji C, Liang C, Qiu Y, Chen B, Zhang J. Zhao Y, et al. Among authors: wang j. Adv Ther. 2025 Sep;42(9):4527-4539. doi: 10.1007/s12325-025-03284-7. Epub 2025 Jul 12. Adv Ther. 2025. PMID: 40650707 Clinical Trial.
Molecular discoveries in microbial DMSP synthesis.
Carrión O, Zhu XY, Williams BT, Wang J, Zhang XH, Todd JD. Carrión O, et al. Among authors: wang j. Adv Microb Physiol. 2023;83:59-116. doi: 10.1016/bs.ampbs.2023.03.001. Epub 2023 Jun 1. Adv Microb Physiol. 2023. PMID: 37507162 Review.
Efficacy and Safety of Anti-IL-4Rα Stapokibart in Elderly Patients With Moderate-To-Severe Atopic Dermatitis.
Zhao Y, Zhang L, Wu L, Yang B, Wang J, Li Y, Diao Q, Li J, Sun Q, Zhu X, Man X, Wang L, Feng Y, Cai T, Zeng H, Li L, Lu J, Ren H, Li F, Lu Q, Tao X, Xiao R, Ji C, Sun J, Qiu Y, Chen B, Zhang J. Zhao Y, et al. Among authors: wang j. Int J Dermatol. 2026 Jun;65(6):1185-1194. doi: 10.1111/ijd.70175. Epub 2025 Nov 21. Int J Dermatol. 2026. PMID: 41272415 Free PMC article. Clinical Trial.
Antiviral RNA interference in mammals.
Ding SW, Han Q, Wang J, Li WX. Ding SW, et al. Among authors: wang j. Curr Opin Immunol. 2018 Oct;54:109-114. doi: 10.1016/j.coi.2018.06.010. Epub 2018 Jul 17. Curr Opin Immunol. 2018. PMID: 30015086 Free PMC article. Review.
377 results